Revolution Medicines

At Revolution Medicines, we aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. We challenge assumptions, act on what the science reveals, and push beyond convention to tackle some of the most difficult-to-treat cancers.

Our differentiated, platform-driven approach targets RAS in its active, ON state—unlocking a fundamentally new way to inhibit RAS. We are advancing a broad, integrated pipeline of inhibitors with the ambition to establish RAS(ON) inhibition as the backbone for treating RAS-addicted cancers while continuing to pioneer the next generation of innovation.

We follow the science and act on it with urgency to turn insights into new treatments—because for patients, the stakes are deeply personal, measured in time and quality of life.

For additional information on our guidelines, please visit https://www.revmed.com/social-media-community-guidelines/